Temp Alt Text Temp Alt Text

We pioneered complement biology, spurring new treatments for devastating disorders. We work to advance healthcare through innovative diagnostics and proactive transparency.
Temp Alt Text
Victor, diagnosed with PNH at 27 years old

REDEFINE Highlights


Center of Excellence formed in 2019


Patients diagnosed with nephronophthisis through collaboration with 100,000 Genomes Project


Advancing programs in rare hematology, nephrology, neurology, metabolics and cardiology
Victor, diagnosed with PNH at 27 years old

Voluntarily Sharing Data

To be sure we are doing everything we can to advance the treatment of rare diseases, Alexion voluntarily shares de-identified data we gather from company-sponsored clinical trials to encourage further research, as appropriate. Only data that cannot be identified back to individual trial participants is shared. In 2019, we formed an internal, cross-functional Transparency and Disclosure Committee to further our voluntary data sharing efforts from clinical studies.
Read More
An Alexion employee working in a lab

Advancing Shared Research

We support clinically and scientifically sound independent research to generate evidence and ultimately contribute to advancing patient care. Through our Externally Sponsored Research (ESR) program, we receive, review and respond to unsolicited proposals from external sponsors requesting funding. Data generated by Alexion-funded ESR studies have been published in peer-reviewed journals, including three publications in 2019. We also encourage academic scientists and researchers to submit proposals for work focused on preclinical translation of scientific discoveries into therapies for rare disorders under Alexion’s Discovery Partnerships program.
Read More